Latest Quinazolines Stories
LONDON, June 7, 2010 /PRNewswire-FirstCall/ -- Results from ZETA, a phase III study in patients with advanced medullary thyroid cancer (MTC), showed that treatment with the investigational drug vandetanib significantly extended Progression Free Survival (PFS), the primary endpoint of the study, by demonstrating a 54% reduction in the rate of progression compared to placebo (HR=0.46, p=0.0001).
Combination of targeted agent, chemotherapy improves progression-free survival; therapy inhibits both VEGFR and EGFR.
Testing for the presence of specific cancer protein 'fingerprints' in the blood of lung cancer patients may be a useful means of identifying a subgroup whose tumors are more likely to shrink when treated with the drug erlotinib, especially when other testing methods are unavailable.
The recent approval of Europe's first personalized treatment for lung cancer heralds the arrival of a new era for lung cancer treatment that will demand significant changes to the way cancer specialists and other hospital doctors work.
BROOMFIELD, Colo., April 30 /PRNewswire/ -- Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented today at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland.
Although more than two fifths of lung cancers are diagnosed in patients over 70, data from clinical trials on the safest and most effective treatments for this age group are scarce.
NUTLEY, N.J., April 22 /PRNewswire/ -- Roche announced today that Mike Burgess, M.D., Ph.D., has been named Head of the Oncology Discovery and Translational Area (DTA) (1), effective immediately.
BROOMFIELD, Colo., April 19 /PRNewswire/ -- Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone, M.D., Ph.D., Professor of Medicine and Cancer Biology, Vanderbilt University School of Medicine, on Friday, April 30th at the 2nd European Lung Cancer Conference to be held in Geneva, Switzerland.
Biopsy-based study tilts field toward personalized treatment, more efficient clinical trials.
SAN DIEGO, April 6 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. today announced the completion of patient enrollment to its APRiCOT-L study, a phase II clinical trial of its oral, once-daily anti-cancer agent, CapoxigemÂ® (apricoxib, TG01), in non-small cell lung cancer (NSCLC).